Predictive value of serum bradykinin and desArg9-bradykinin levels for chemotherapeutic responses in active tuberculosis patients: A retrospective case series

Tuberculosis

Volumn 101, Issue , 2016, Pages S109-S118

  Qian, Xu ^a,b   Nguyen, Duc T M ^a   Li, Yaojun ^a   Lyu, Jianxin ^b   Graviss, Edward A ^a   Hu, Tony Y ^a,c  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Antibiotics; Bradykinin; Outcome; Recurrence; Treatment response; Tuberculosis

Indexed keywords

AMINOSALICYLIC ACID; BRADYKININ; BRADYKININ[1-8]; CIPROFLOXACIN; CYCLOSERINE; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT; BIOLOGICAL MARKER; BRADYKININ, DES-ARG(9)-;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BLOOD BIOCHEMISTRY; CASE STUDY; CLINICAL ARTICLE; CONSOLIDATION CHEMOTHERAPY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTRAPULMONARY TUBERCULOSIS; HUMAN; IMMUNE RESPONSE; INDUCTION CHEMOTHERAPY; LONG TERM CARE; LUNG TUBERCULOSIS; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SPUTUM CULTURE; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BLOOD; DOWN REGULATION; ISOLATION AND PURIFICATION; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; MICROBIOLOGY; NANOMEDICINE; PILOT STUDY; PROCEDURES; RECURRENT DISEASE; REMISSION; SPUTUM; TIME FACTOR; TUBERCULOSIS;

ADULT; ANTITUBERCULAR AGENTS; BIOMARKERS; BRADYKININ; DOWN-REGULATION; HUMANS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; NANOMEDICINE; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SPUTUM; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 85002213676     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2016.09.022     Document Type: Article

References (51)

1. [1] Mitchison, D., Davies, G., The chemotherapy of tuberculosis: past, present and future. Int J Tuberc lung Dis Off J Int Union Against Tuberc Lung Dis 16:6 (2012), 724–732.
2. [2] World Health Organization, Global tuberculosis report., 2015 Available online http://www.who.int/tb/data [Internet].
3. [3] Jindani, A., Nunn, A.J., Enarson, D.A., Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 364:9441 (2004), 1244–1251.
4. [4] van der Werf, M.J., Langendam, M.W., Huitric, E., Manissero, D., Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysis. Eur Respir J 39:6 (2012), 1511–1519.
5. [5] Lenaerts, A., Barry, C.E. 3rd, Dartois, V., Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses. Immunol Rev 264:1 (2015), 288–307.
6. [6] Wallis, R.S., Doherty, T.M., Onyebujoh, P., Vahedi, M., Laang, H., Olesen, O., et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis 9:3 (2009), 162–172.
7. [7] Friedrich, S.O., Rachow, A., Saathoff, E., Singh, K., Mangu, C.D., Dawson, R., et al. Pan African consortium for the evaluation of anti-tuberculosis A. Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. Lancet Respir Med 1:6 (2013), 462–470.
8. [8] Chee, C.B., KhinMar, K.W., Gan, S.H., Barkham, T.M., Koh, C.K., Shen, L., et al. Tuberculosis treatment effect on T-cell interferon-gamma responses to Mycobacterium tuberculosis-specific antigens. Eur Respir J 36:2 (2010), 355–361.
9. [9] Hill, P.C., Brookes, R.H., Fox, A., Jackson-Sillah, D., Jeffries, D.J., Lugos, M.D., et al. Longitudinal assessment of an ELISPOT test for mycobacterium tuberculosis infection. PLoS Med, 4(6), 2007, e192.
10. [10] Oschatz, C., Maas, C., Lecher, B., Jansen, T., Bjorkqvist, J., Tradler, T., et al. Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity 34:2 (2011), 258–268.
11. [11] Oehmcke, S., Herwald, H., Contact system activation in severe infectious diseases. J Mol Med 88:2 (2010), 121–126.
12. [12] Kaplan, A.P., Joseph, K., Shibayama, Y., Nakazawa, Y., Ghebrehiwet, B., Reddigari, S., et al. Bradykinin formation. Plasma and tissue pathways and cellular interactions. Clin Rev Allergy Immunol 16:4 (1998), 403–429.
13. [13] Frick, I.M., Akesson, P., Herwald, H., Morgelin, M., Malmsten, M., Nagler, D.K., et al. The contact system–a novel branch of innate immunity generating antibacterial peptides. EMBO J 25:23 (2006), 5569–5578.
14. [14] Frick, I.M., Bjorck, L., Herwald, H., The dual role of the contact system in bacterial infectious disease. Thromb Haemost 98:3 (2007), 497–502.
15. [15] Phagoo, S.B., Reddi, K., Silvallana, B.J., Leeb-Lundberg, L.M., Warburton, D., Infection-induced kinin B1 receptors in human pulmonary fibroblasts: role of intact pathogens and p38 mitogen-activated protein kinase-dependent signaling. J Pharmacol Exp Ther 313:3 (2005), 1231–1238.
16. [16] Matsumoto, K., Yamamoto, T., Kamata, R., Maeda, H., Pathogenesis of serratial infection: activation of the Hageman factor-prekallikrein cascade by serratial protease. J Biochem 96:3 (1984), 739–749.
17. [17] Potempa, J., Pike, R.N., Corruption of innate immunity by bacterial proteases. J Innate Immun 1:2 (2009), 70–87.
18. [18] Koyama, S., Sato, E., Numanami, H., Kubo, K., Nagai, S., Izumi, T., Bradykinin stimulates lung fibroblasts to release neutrophil and monocyte chemotactic activity. Am J Respir Cell Mol Biol 22:1 (2000), 75–84.
19. [19] Sato, E., Koyama, S., Nomura, H., Kubo, K., Sekiguchi, M., Bradykinin stimulates alveolar macrophages to release neutrophil, monocyte, and eosinophil chemotactic activity. J Immunol 157:7 (1996), 3122–3129.
20. [20] Bertram, C.M., Baltic, S., Misso, N.L., Bhoola, K.D., Foster, P.S., Thompson, P.J., et al. Expression of kinin B1 and B2 receptors in immature, monocyte-derived dendritic cells and bradykinin-mediated increase in intracellular Ca2+ and cell migration. J Leukoc Biol 81:6 (2007), 1445–1454.
21. [21] Aliberti, J., Viola, J.P., Vieira-de-Abreu, A., Bozza, P.T., Sher, A., Scharfstein, J., Cutting edge: bradykinin induces IL-12 production by dendritic cells: a danger signal that drives Th1 polarization. J Immunol 170:11 (2003), 5349–5353.
22. [22] Amigorena, S., Savina, A., Intracellular mechanisms of antigen cross presentation in dendritic cells. Curr Opin Immunol 22:1 (2010), 109–117.
23. [23] Leeb-Lundberg, L.M., Marceau, F., Muller-Esterl, W., Pettibone, D.J., Zuraw, B.L., International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 57:1 (2005), 27–77.
24. [24] Erdös, E.G.S.R., Metabolism of bradykinin by peptidases in health and disease, the kinin system. 1997, Academic Press, London.
25. [25] Couture, R., Harrisson, M., Vianna, R.M., Cloutier, F., Kinin receptors in pain and inflammation. Eur J Pharmacol 429:1–3 (2001), 161–176.
26. [26] Dray, A., Perkins, M., Bradykinin and inflammatory pain. Trends Neurosci 16:3 (1993), 99–104.
27. [27] Christiansen, S.C., Eddleston, J., Woessner, K.M., Chambers, S.S., Ye, R., Pan, Z.K., et al. Up-regulation of functional kinin B1 receptors in allergic airway inflammation. J Immunol 169:4 (2002), 2054–2060.
28. [28] Marceau, F., Hess, J.F., Bachvarov, D.R., The B1 receptors for kinins. Pharmacol Rev 50:3 (1998), 357–386.
29. [29] Schremmer-Danninger, E., Offner, A., Siebeck, M., Roscher, A.A., B1 bradykinin receptors and carboxypeptidase M are both upregulated in the aorta of pigs after LPS infusion. Biochem Biophys Res Commun 243:1 (1998), 246–252.
30. [30] Raynaud, C., Guilhot, C., Rauzier, J., Bordat, Y., Pelicic, V., Manganelli, R., et al. Phospholipases C are involved in the virulence of Mycobacterium tuberculosis. Mol Microbiol 45:1 (2002), 203–217.
31. [31] Christopher, J., Velarde, V., Jaffa, A.A., Induction of B(1)-kinin receptors in vascular smooth muscle cells: cellular mechanisms of map kinase activation. Hypertension 38:3 Pt 2 (2001), 602–605.
32. [32] Ahluwalia, A., Perretti, M., Involvement of bradykinin B1 receptors in the polymorphonuclear leukocyte accumulation induced by IL-1 beta in vivo in the mouse. J Immunol 156:1 (1996), 269–274.
33. [33] Araujo, R.C., Kettritz, R., Fichtner, I., Paiva, A.C., Pesquero, J.B., Bader, M., Altered neutrophil homeostasis in kinin B1 receptor-deficient mice. Biol Chem 382:1 (2001), 91–95.
34. [34] Wu, H.J., Li, Y., Fan, J., Deng, Z., Hu, Z., Liu, X., et al. Antibody-free detection of Mycobacterium tuberculosis antigen using customized nanotraps. Anal Chem 86:4 (2014), 1988–1996.
35. [35] Hu, Y., Peng, Y., Lin, K., Shen, H., Brousseau, L.C. 3rd, Sakamoto, J., et al. Surface engineering on mesoporous silica chips for enriching low molecular weight phosphorylated proteins. Nanoscale 3:2 (2011), 421–428.
36. [36] El Sahly, H.M., Wright, J.A., Soini, H., Bui, T.T., Williams-Bouyer, N., Escalante, P., et al. Recurrent tuberculosis in Houston, Texas: a population-based study. Int J Tuberc Lung Dis Off J Int Union Against Tuberc Lung Dis 8:3 (2004), 333–340.
37. [37] Qiu, L., Teeter, L.D., Liu, Z., Ma, X., Musser, J.M., Graviss, E.A., Diagnostic associations between pleural and pulmonary tuberculosis. J Infect 53:6 (2006), 377–386.
38. [38] Diagnostic Standards and Classification of Tuberculosis in Adults and Children, This official statement of the american thoracic society and the centers for disease Control and prevention was adopted by the ATS board of directors, july 1999. This statement was endorsed by the council of the infectious disease society of America, september 1999. Am J Respir Crit Care Med 161:4 Pt 1 (2000), 1376–1395.
39. [39] Phagoo, S.B., Poole, S., Leeb-Lundberg, L.M., Autoregulation of bradykinin receptors: agonists in the presence of interleukin-1beta shift the repertoire of receptor subtypes from B2 to B1 in human lung fibroblasts. Mol Pharmacol 56:2 (1999), 325–333.
40. [40] Tsakiris, I., Torocsik, D., Gyongyosi, A., Dozsa, A., Szatmari, I., Szanto, A., et al. Carboxypeptidase-M is regulated by lipids and CSFs in macrophages and dendritic cells and expressed selectively in tissue granulomas and foam cells. Lab Investig J Tech Methods Pathol 92:3 (2012), 345–361.
41. [41] Prat, A., Weinrib, L., Becher, B., Poirier, J., Duquette, P., Couture, R., et al. Bradykinin B1 receptor expression and function on T lymphocytes in active multiple sclerosis. Neurology 53:9 (1999), 2087–2092.
42. [42] Prat, A., Biernacki, K., Pouly, S., Nalbantoglu, J., Couture, R., Antel, J.P., Kinin B1 receptor expression and function on human brain endothelial cells. J Neuropathol Exp Neurol 59:10 (2000), 896–906.
43. [43] Stadnicki, A., Pastucha, E., Nowaczyk, G., Mazurek, U., Plewka, D., Machnik, G., et al. Immunolocalization and expression of kinin B1R and B2R receptors in human inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 289:2 (2005), G361–G366.
44. [44] American thoracic S, cdc, infectious diseases society of a. Treatment of tuberculosis. MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Reports/Centers Dis Control 52:RR-11 (2003), 1–77.
45. [45] Berry, M.P., Graham, C.M., McNab, F.W., Xu, Z., Bloch, S.A., Oni, T., et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466:7309 (2010), 973–977.
46. [46] Cliff, J.M., Cho, J.E., Lee, J.S., Ronacher, K., King, E.C., van Helden, P., et al. Excessive cytolytic responses predict tuberculosis relapse after apparently successful treatment. J Infect Dis 213:3 (2016), 485–495.
47. [47] Jayakumar, A., Vittinghoff, E., Segal, M.R., MacKenzie, W.R., Johnson, J.L., Gitta, P., et al. Serum biomarkers of treatment response within a randomized clinical trial for pulmonary tuberculosis. Tuberculosis 95:4 (2015), 415–420.
48. [48] De Groote, M.A., Nahid, P., Jarlsberg, L., Johnson, J.L., Weiner, M., Muzanyi, G., et al. Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment. PloS One, 8(4), 2013, e61002.
49. [49] Almeida, M.L., Barbieri, M.A., Gurgel, R.Q., Abdurrahman, S.T., Baba, U.A., Hart, C.A., et al. alpha1-acid glycoprotein and alpha1-antitrypsin as early markers of treatment response in patients receiving the intensive phase of tuberculosis therapy. Trans R Soc Trop Med Hyg 103:6 (2009), 575–580.
50. [50] Koyama, S., Rennard, S.I., Robbins, R.A., Bradykinin stimulates bronchial epithelial cells to release neutrophil and monocyte chemotactic activity. Am J Physiol 269:1 Pt 1 (1995), L38–L44.
51. [51] Bengtson, S.H., Sanden, C., Morgelin, M., Marx, P.F., Olin, A.I., Leeb-Lundberg, L.M., et al. Activation of TAFI on the surface of Streptococcus pyogenes evokes inflammatory reactions by modulating the kallikrein/kinin system. J Innate Immun 1:1 (2009), 18–28.